The post Propanc Biopharma Secures $100M to Build Crypto Treasury appeared on BitcoinEthereumNews.com. The money raised will also be used to fund Propanc’s upcoming cancer therapy trials. The biotech firm sees the move as a “transformative phase” to strengthen its balance sheet and advance its proenzyme-based treatment. However, investors reacted negatively by sending its stock down 12%. . Propanc Turns to Crypto Australia-based Propanc Biopharma secured up to $100 million from Hexstone Capital, a crypto-focused family office, to establish a digital asset treasury as part of its plan to fund upcoming human trials for its cancer therapy product. The private placement, structured through convertible preferred stock, begins with an initial $1 million investment and allows for up to $99 million in follow-on funding over the next 12 months. Announcement from Porpanc Propanc said the proceeds will be used to develop its digital asset treasury and accelerate the advancement of its lead oncology therapy, PRP, which targets metastatic cancer from solid tumors and is expected to enter human trials in the second half of 2026. CEO James Nathanielsz described the crypto treasury initiative as a “transformative phase” for the company, and said that it will strengthen its balance sheet and advance its proenzyme-based cancer treatment platform. While Propanc did not disclose which digital assets it plans to buy, Hexstone’s portfolio includes investments in Bitcoin, Ethereum, Solana, Injective, and other cryptocurrencies. The move places Propanc among the growing number of biotech companies, like Sonnet BioTherapeutics and Sharps Technology, that have turned to crypto strategies to attract new investors. Despite the bold initiative, Propanc’s stock price fell 12% on the Nasdaq after the announcement. This certainly reflects some of the market sentiment toward crypto treasury strategies, which recently struggled due to declining valuations for major Bitcoin-holding companies. Propanc’s stock price over the past 24 hours (Source: Google Finance) Strategy is the largest corporate Bitcoin holder, and… The post Propanc Biopharma Secures $100M to Build Crypto Treasury appeared on BitcoinEthereumNews.com. The money raised will also be used to fund Propanc’s upcoming cancer therapy trials. The biotech firm sees the move as a “transformative phase” to strengthen its balance sheet and advance its proenzyme-based treatment. However, investors reacted negatively by sending its stock down 12%. . Propanc Turns to Crypto Australia-based Propanc Biopharma secured up to $100 million from Hexstone Capital, a crypto-focused family office, to establish a digital asset treasury as part of its plan to fund upcoming human trials for its cancer therapy product. The private placement, structured through convertible preferred stock, begins with an initial $1 million investment and allows for up to $99 million in follow-on funding over the next 12 months. Announcement from Porpanc Propanc said the proceeds will be used to develop its digital asset treasury and accelerate the advancement of its lead oncology therapy, PRP, which targets metastatic cancer from solid tumors and is expected to enter human trials in the second half of 2026. CEO James Nathanielsz described the crypto treasury initiative as a “transformative phase” for the company, and said that it will strengthen its balance sheet and advance its proenzyme-based cancer treatment platform. While Propanc did not disclose which digital assets it plans to buy, Hexstone’s portfolio includes investments in Bitcoin, Ethereum, Solana, Injective, and other cryptocurrencies. The move places Propanc among the growing number of biotech companies, like Sonnet BioTherapeutics and Sharps Technology, that have turned to crypto strategies to attract new investors. Despite the bold initiative, Propanc’s stock price fell 12% on the Nasdaq after the announcement. This certainly reflects some of the market sentiment toward crypto treasury strategies, which recently struggled due to declining valuations for major Bitcoin-holding companies. Propanc’s stock price over the past 24 hours (Source: Google Finance) Strategy is the largest corporate Bitcoin holder, and…

Propanc Biopharma Secures $100M to Build Crypto Treasury

2025/11/11 13:35
2분 읽기
이 콘텐츠에 대한 의견이나 우려 사항이 있으시면 crypto.news@mexc.com으로 연락주시기 바랍니다

The money raised will also be used to fund Propanc’s upcoming cancer therapy trials. The biotech firm sees the move as a “transformative phase” to strengthen its balance sheet and advance its proenzyme-based treatment. However, investors reacted negatively by sending its stock down 12%. .

Propanc Turns to Crypto

Australia-based Propanc Biopharma secured up to $100 million from Hexstone Capital, a crypto-focused family office, to establish a digital asset treasury as part of its plan to fund upcoming human trials for its cancer therapy product. The private placement, structured through convertible preferred stock, begins with an initial $1 million investment and allows for up to $99 million in follow-on funding over the next 12 months.

Announcement from Porpanc

Propanc said the proceeds will be used to develop its digital asset treasury and accelerate the advancement of its lead oncology therapy, PRP, which targets metastatic cancer from solid tumors and is expected to enter human trials in the second half of 2026. CEO James Nathanielsz described the crypto treasury initiative as a “transformative phase” for the company, and said that it will strengthen its balance sheet and advance its proenzyme-based cancer treatment platform.

While Propanc did not disclose which digital assets it plans to buy, Hexstone’s portfolio includes investments in Bitcoin, Ethereum, Solana, Injective, and other cryptocurrencies. The move places Propanc among the growing number of biotech companies, like Sonnet BioTherapeutics and Sharps Technology, that have turned to crypto strategies to attract new investors.

Despite the bold initiative, Propanc’s stock price fell 12% on the Nasdaq after the announcement. This certainly reflects some of the market sentiment toward crypto treasury strategies, which recently struggled due to declining valuations for major Bitcoin-holding companies.

Propanc’s stock price over the past 24 hours (Source: Google Finance)

Strategy is the largest corporate Bitcoin holder, and saw its market cap fall 40+% since July. Japan’s Metaplanet, which was once among the best-performing stocks of the year, dropped roughly 55% since June. 

Other firms with crypto-heavy treasuries have also been forced to sell portions of their Bitcoin holdings to cover debt obligations, which raises serious concerns about the sustainability of such strategies.

Source: https://coinpaper.com/12248/propanc-biopharma-secures-100-m-to-build-crypto-treasury

시장 기회
Movement 로고
Movement 가격(MOVE)
$0.01766
$0.01766$0.01766
+0.05%
USD
Movement (MOVE) 실시간 가격 차트
면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, crypto.news@mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

$30,000 in PRL + 15,000 USDT

$30,000 in PRL + 15,000 USDT$30,000 in PRL + 15,000 USDT

Deposit & trade PRL to boost your rewards!